Companion Diagnostics Market

Companion Diagnostics Market by Product & Service (Assay, Kit, Software & Service), Technology (PCR, NGS, ISH, IHC), Indication (Breast, Lung & Gastric Cancer, Neurological Disease), End-User (Pharma Companies, CRO), Region - Global Forecast to 2025

Report Code: MD 5463 Jun, 2020, by marketsandmarkets.com

[333 Pages Report] The companion diagnostics market is expected to reach USD 6.8 billion by 2025 from USD 3.7 billion in 2020, at a CAGR of 12.9% during the forecast period of 2020 to 2025. Advantages of companion diagnostics, the growing need for targeted therapy, the rising importance of personalized medicine, the increasing global incidence of cancer, and the ever-increasing application areas of companion diagnostics are driving the growth of the global companion diagnostics industry. The increasing demand for next-generation sequencing, the growing significance of companion diagnostics in drug development, and the rising number of clinical trials are the major factors driving the growth of this market.

In this report, the companion diagnostics market is segmented on the basis of products & services, technology, indication, end user, and region.

Companion Diagnostics Market

COVID-19 Impact on the Global Companion Diagnostics Market

The companion diagnostics market includes major Tier I and II companies like Roche Diagnostics, Agilent Technologies, Qiagen, Thermo Fisher, and Abbott Laboratories. These suppliers have their manufacturing facilities spread across various countries across Asia Pacific, Europe, North America, South America, and RoW. The lockdown and restrictions related to social distancing implemented in these COVID-19 countries had negatively affected the supply chain of these products.

Companion diagnostics Market Dynamics

Drivers: Growing need for targeted therapy

With advances in genetic sequencing and genomics, it is now widely believed that drugs can work differently in different individuals. A better understanding of the genetic characteristics or biomarkers of an individual can promote the practice of administering “the right drug, at the right time, at the right dose, for the right person.” Pharmaceutical and biopharmaceutical companies are continuously attempting to implement patient-selection diagnostic frameworks in the earlier stages of drug development to provide targeted therapies to the right candidate. This further supports the growth of the companion diagnostics market.

Restrains: High cost of companion diagnostics tests

The high initial cost puts these tests out of reach of a large portion of end users—particularly those in developing countries—in spite of providing assured returns on investment. This prompts end users such as pharma companies, reference laboratories, hospitals, and CROs, which perceive the usage of such diagnostic tests as a burden on their budgets, to opt for third-party companion diagnostic services.

Opportunities: Increasing demand for next-generation sequencing

NGS-based companion diagnostic tests aim to unlock molecular information from each patient's tumor genome to guide treatment decisions for cancer therapies. Next-generation sequencing detects multiple biomarkers for multiple drug therapies in a shorter time frame as compared to other sequencing techniques. The use of NGS panels for biomarker measurement in one test has the potential to help in the treatment of many different types of cancers.

Challenges:Shortage of trained professionals

Companion diagnostic testing is a complex and technical process that demands well-trained resources. The knowledge of companion diagnostic technologies is vital for effectively carrying out tests. CDx assays are sensitive to the quantity and purity of the samples used, and small deviations can lead to erroneous and variable inferences. In addition, different types of assays, kits, tests, and software & services are used in companion diagnostics; this increases the cost of production. Hence, it is mandatory that all laboratories and setups be well-versed with these technologies.

Polymerase chain reaction (PCR) segment to account for the largest share of the companion diagnostics market, by technology, in 2019

The polymerase chain reaction segment is expected to dominate the companion diagnostics market in 2019. The large share of this segment can be attributed to the ease of use and widespread availability of PCR kits & reagents in companion diagnostic testing, growing applications of PCR in the high-throughput detection of mutants with a limited or low allele frequency of genes, and high turnaround time of PCR as compared to other technologies.

Pharmaceutical & biopharmaceutical companies are estimated to be the largest end-users of companion diagnostics in 2019

Pharmaceutical & biopharmaceutical companies are expected to account for the largest share of the companion diagnostics market in 2019. The large share of this segment can majorly be attributed to the extensive usage of companion diagnostics in these industries owing to their growing prominence in drug development and the increasing importance of companion diagnostic biomarkers. The increasing demand for personalized medicine as well as the high demand for targeted therapies for various diseases and disorders are also expected to drive the demand and uptake of companion diagnostics among pharmaceutical & biopharmaceutical companies.

Asia Pacific market to witness the highest growth during the forecast period

The companion diagnostics market in the APAC is estimated to grow at the highest CAGR during the forecast period. The high incidence of cancer, increasing proteomics & genomics research, growing research funding, rising investments by pharmaceutical and biotechnology companies, and growing awareness about personalized therapeutics in several APAC countries are expected to drive the growth of the APAC market.

Companion Diagnostics Market by Region

Key Market Players

The companion diagnostics market is dominated by a few globally established players such as Roche Diagnostics, Agilent Technologies, Qiagen, Thermo Fisher, and Abbott Laboratories.

Scope of the Report

Report Metric

Details

Market size available for years

2017–2025

Base year considered

2019

Forecast period

2020–2025

Forecast units

Value (USD Million)

Segments covered

Products and Services, Technology, Indication, End User

Geographies covered

North America, Europe, Asia Pacific, Latin America, Middle East and Africa

Companies covered

The major market players include F. Hoffmann-La Roche AG (Switzerland), Agilent Technologies, Inc. (US), QIAGEN N.V. (Germany), Abbott Laboratories, Inc. (US), Almac Group (UK), Danaher Corporation (US), Illumina, Inc. (US), bioMιrieux SA (France), Myriad Genetics, Inc., (US), Sysmex Corporation (Japan), Thermo Fisher Scientific Inc. (US), Abnova Corporation (Taiwan), Guardant Health, Inc. (US), Icon Plc (Ireland), Biogenex Laboratories, Inc. (US)

The study categorizes the companion diagnostics market based on products & services, technology, indication, end user, component at the regional and global level.

Companion diagnostics Market, by Product & Service

  • Assay kits & Reagents
  • Software & Services

Companion diagnostics Market, by Technology

  • Polymerase Chain Reaction (PCR) 
  • In Situ Hybridization (ISH) 
  • Next-Generation Sequencing (NGS)
  • Immunohistochemistry (IHC) 
  • Others (Multiplex Assay and Cellular Imaging Technologies)

Companion diagnostics Market, by Indication

  • Cardiovascular
  • Neurological Diseases
  • Cancer
    • Breast Cancer 
    • Lung Cancer 
    • Colorectal Cancer 
    • Melanoma 
    • Gastric Cancer 
  • Infectious Diseases 
  • Others (inflammatory and inherited diseases)

Companion diagnostics Market, by End User

  • Pharmaceutical & Biopharmaceutical Companies
  • Reference Laboratories
  • CROs
  • Others (Physicians, Hospitals, Academic Medical Centers, Payers)

Companion diagnostics Market, by Region

  • North America
    • US
    • Canada
  • Europe
    • Germany
    • UK
    • Switzerland
    • France
    • Italy
    • Spain
  • Rest of Europe
  • Asia Pacific
    • China
    • Japan
    • India
    • Australia
    • Rest of Asia Pacific
  • Latin America
    • Brazil
    • Mexico
    • Rest of Latin America
  • Middle East & Africa

Recent Developments

  • In June 2020, Thermo Fisher Scientific Inc. and Agios Pharmaceuticals strategic partnership was made to codevelop a second companion diagnostics platform for oncology.
  • In January 2020, QIAGEN N.V. and Amgen collaborated with the aim to develop tissue-based companion diagnostics for the identification of patients with cancers that have the KRAS G12C mutation.
  • In May 2019, QIAGEN N.V. launched the therascreen PIK3CA RGQ PCR Kit in PIQRAY (alpelisib) therapy in the US to enhance its product portfolio in the companion diagnostics market.
  • In April 2019, Myriad Genetics, Inc. (US) and AstraZeneca plc (UK) and Merck Group (Germany) entered into a partnership, to identify unmet medical needs in men related to metastatic castration-resistant prostate cancer and expand the company's patient access in the market.

Frequently Asked Questions (FAQ):

To speak to our analyst for a discussion on the above findings, click Speak to Analyst

TABLE OF CONTENTS

1 INTRODUCTION (Page No. - 42)
    1.1 OBJECTIVES OF THE STUDY
    1.2 MARKET DEFINITION
           1.2.1 INCLUSIONS & EXCLUSIONS
    1.3 MARKET SCOPE
           1.3.1 MARKETS COVERED
           1.3.2 YEARS CONSIDERED FOR THE STUDY
    1.4 CURRENCY
        TABLE 1 STANDARD CURRENCY CONVERSION RATES
    1.5 LIMITATIONS
    1.6 STAKEHOLDERS
    1.7 SUMMARY OF CHANGES

2 RESEARCH METHODOLOGY (Page No. - 47)
    2.1 RESEARCH DATA
        FIGURE 1 RESEARCH DESIGN
           2.1.1 SECONDARY DATA
                    2.1.1.1 Key data from secondary sources
           2.1.2 PRIMARY DATA
                 FIGURE 2 PRIMARY SOURCES
                    2.1.2.1 Key data from primary sources
                    2.1.2.2 Key industry insights
                            FIGURE 3 BREAKDOWN OF PRIMARY INTERVIEWS: BY COMPANY TYPE, DESIGNATION, AND REGION
    2.2 MARKET SIZE ESTIMATION
        FIGURE 4 MARKET SIZE ESTIMATION: REVENUE SHARE ANALYSIS
        FIGURE 5 REVENUE SHARE ANALYSIS ILLUSTRATION
        FIGURE 6 MARKET SIZE APPROACH
        FIGURE 7 TOP-DOWN APPROACH
    2.3 MARKET BREAKDOWN AND DATA TRIANGULATION
        FIGURE 8 DATA TRIANGULATION METHODOLOGY
    2.4 MARKET SHARE ANALYSIS
    2.5 ASSUMPTIONS FOR THE STUDY

3 EXECUTIVE SUMMARY (Page No. - 57)
  FIGURE 9 COMPANION DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2020 VS. 2025 (USD BILLION)
  FIGURE 10 COMPANION DIAGNOSTICS MARKET, BY TECHNOLOGY, 2020 VS. 2025 (USD BILLION)
  FIGURE 11 COMPANION DIAGNOSTICS MARKET, BY INDICATION, 2020 VS. 2025 (USD BILLION)
  FIGURE 12 COMPANION DIAGNOSTICS MARKET, BY END USER, 2020 VS. 2025 (USD BILLION)
  FIGURE 13 GEOGRAPHICAL SNAPSHOT OF THE COMPANION DIAGNOSTICS MARKET

4 PREMIUM INSIGHTS (Page No. - 61)
    4.1 COMPANION DIAGNOSTICS MARKET OVERVIEW
        FIGURE 14 INCREASING DEMAND FOR TARGETED THERAPIES AND PERSONALIZED MEDICINE IN THE PHARMACEUTICAL INDUSTRY TO DRIVE MARKET GROWTH
    4.2 ASIA PACIFIC: COMPANION DIAGNOSTICS MARKET, BY END USER (2019)
        FIGURE 15 PHARMACEUTICAL & BIOPHARMACEUTICAL COMPANIES COMMANDED THE LARGEST SHARE OF THE APAC COMPANION DIAGNOSTICS MARKET IN 2019
    4.3 REGIONAL MIX: COMPANION DIAGNOSTICS MARKET
        FIGURE 16 ASIA PACIFIC TO WITNESS THE HIGHEST GROWTH IN THE FORECAST PERIOD
    4.4 COMPANION DIAGNOSTICS MARKET: DEVELOPED VS. DEVELOPING COUNTRIES
        FIGURE 17 DEVELOPING COUNTRIES TO REGISTER HIGHER GROWTH DURING THE FORECAST PERIOD
    4.5 GEOGRAPHICAL SNAPSHOT OF THE COMPANION DIAGNOSTICS MARKET
        FIGURE 18 CHINA TO GROW AT THE HIGHEST CAGR DURING THE FORECAST PERIOD

5 MARKET OVERVIEW (Page No. - 65)
    5.1 INTRODUCTION
    5.2 MARKET DYNAMICS
        FIGURE 19 COMPANION DIAGNOSTICS MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES
           5.2.1 DRIVERS
                    5.2.1.1 Advantages of companion diagnostics
                    5.2.1.2 Growing need for targeted therapy
                    5.2.1.3 Growing importance of personalized medicine
                            FIGURE 20 GLOBAL LAUNCH OF PERSONALIZED MEDICINE PRODUCTS, 2008–2016
                    5.2.1.4 Increasing global incidence of cancer
                            FIGURE 21 GLOBAL CANCER INCIDENCE, 2008–2030
                    5.2.1.5 Growing application areas of companion diagnostics
           5.2.2 RESTRAINTS
                    5.2.2.1 High cost of companion diagnostic tests
                    5.2.2.2 Uncertain reimbursement scenario in different regions
                            TABLE 2 COMPANION DIAGNOSTICS REIMBURSEMENT SCENARIO WORLDWIDE
           5.2.3 OPPORTUNITIES
                    5.2.3.1 Increasing demand for next-generation sequencing
                            TABLE 3 PARTNERSHIPS & COLLABORATIONS FOR DEVELOPING NGS-BASED COMPANION DIAGNOSTIC TESTS
                    5.2.3.2 Growing significance of companion diagnostics in drug development
                    5.2.3.3 Increasing number of clinical trials
                            TABLE 4 LIST OF CLINICAL TRIALS FOR COMPANION DIAGNOSTICS
           5.2.4 CHALLENGES
                    5.2.4.1 Impact of the COVID-19 pandemic
                    5.2.4.2 Shortage of trained professionals

6 INDUSTRY INSIGHTS (Page No. - 74)
    6.1 INTRODUCTION
    6.2 INDUSTRY TRENDS
           6.2.1 IMPACT OF THE COVID-19 PANDEMIC ON THE COMPANION DIAGNOSTICS MARKET
                 FIGURE 22 IMPACT OF COVID-19 ON THE COMPANION DIAGNOSTICS MARKET
           6.2.2 GROWING FOCUS ON LIQUID BIOPSY IN COMPANION DIAGNOSTICS
           6.2.3 INCREASING COLLABORATIONS
                 TABLE 5 RECENT COLLABORATIONS IN THE COMPANION DIAGNOSTICS MARKET
    6.3 REGULATORY ANALYSIS
           6.3.1 NORTH AMERICA
                    6.3.1.1 US
                            TABLE 6 US: CLASSIFICATION OF MEDICAL DEVICES
                            FIGURE 23 PREMARKET NOTIFICATION: 510(K) APPROVAL FOR COMPANION DIAGNOSTIC PRODUCTS
                    6.3.1.2 Canada
           6.3.2 EUROPE
           6.3.3 ASIA PACIFIC
                    6.3.3.1 Australia
                    6.3.3.2 Japan
                            TABLE 7 JAPAN: CLASSIFICATION OF MEDICAL DEVICES
                    6.3.3.3 China
                            TABLE 8 CHINA: TIME, COST, AND COMPLEXITY OF REGISTRATION PROCESS
                    6.3.3.4 India
                            FIGURE 24 INDIA: REGULATORY PROCESS FOR IVD DEVICES
                            TABLE 9 INDIA: TIME, COST, AND COMPLEXITY OF REGISTRATION PROCESS
           6.3.4 BRAZIL
    6.4 PRODUCT PIPELINE ANALYSIS
        TABLE 10 COMPANION DIAGNOSTICS PRODUCT PIPELINE ANALYSIS, BY MARKET PLAYER: CURRENT MARKET SCENARIO

7 COMPANION DIAGNOSTICS MARKET, BY PRODUCT & SERVICE (Page No. - 87)
    7.1 INTRODUCTION
        TABLE 11 COMPANION DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2017–2019 (USD MILLION)
        TABLE 12 COMPANION DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2020–2025 (USD MILLION)
    7.2 IMPACT OF COVID-19 ON THE DEMAND AND SUPPLY OF COMPANION DIAGNOSTIC PRODUCTS & SERVICES
    7.3 ASSAYS, KITS, AND REAGENTS
           7.3.1 INCREASING VOLUME OF CDX TESTS PERFORMED IN LABORATORIES TO SUPPORT THE ADOPTION OF ASSAYS & KITS
                 TABLE 13 COMPANION DIAGNOSTIC ASSAYS, KITS, AND REAGENTS MARKET, BY COUNTRY, 2017–2019 (USD MILLION)
                 TABLE 14 COMPANION DIAGNOSTIC ASSAYS, KITS, AND REAGENTS MARKET, BY COUNTRY, 2020–2025 (USD MILLION)
    7.4 SOFTWARE & SERVICES
           7.4.1 NEED FOR EFFECTIVE DATA MANAGEMENT SOFTWARE WITHIN LABORATORIES TO CONTRIBUTE TO MARKET GROWTH
                 TABLE 15 COMPANION DIAGNOSTIC SOFTWARE & SERVICES MARKET, BY COUNTRY, 2017–2019 (USD MILLION)
                 TABLE 16 COMPANION DIAGNOSTIC SOFTWARE & SERVICES MARKET, BY COUNTRY, 2020–2025 (USD MILLION)

8 COMPANION DIAGNOSTICS MARKET, BY TECHNOLOGY (Page No. - 94)
    8.1 INTRODUCTION
        TABLE 17 COMPANION DIAGNOSTICS MARKET, BY TECHNOLOGY, 2017–2019 (USD MILLION)
        TABLE 18 COMPANION DIAGNOSTICS MARKET, BY TECHNOLOGY, 2020–2025 (USD MILLION)
    8.2 IMPACT OF COVID-19 ON THE COMPANION DIAGNOSTIC TECHNOLOGY MARKET
    8.3 POLYMERASE CHAIN REACTION (PCR)
           8.3.1 GROWING APPLICATIONS OF PCR TECHNOLOGIES IN PERSONALIZED MEDICINE AND COMPANION DIAGNOSTICS TO DRIVE GROWTH
                 TABLE 19 COMPARISON OF TISSUE SEQUENCING PLATFORMS FOR THE DETECTION OF RAS/BRAF MUTATION
                 TABLE 20 MAJOR PCR TESTS/KITS AVAILABLE IN THE MARKET
                 TABLE 21 COMPANION DIAGNOSTICS MARKET FOR POLYMERASE CHAIN REACTION, BY COUNTRY, 2017–2019 (USD MILLION)
                 TABLE 22 COMPANION DIAGNOSTICS MARKET FOR POLYMERASE CHAIN REACTION, BY COUNTRY, 2020–2025 (USD MILLION)
    8.4 NEXT-GENERATION SEQUENCING (NGS)
           8.4.1 NGS SEGMENT TO GROW AT HIGHEST CAGR DURING FORECAST PERIOD
                 TABLE 23 MAJOR NGS TESTS/KITS AVAILABLE IN THE MARKET
                 TABLE 24 COMPANION DIAGNOSTICS MARKET FOR NEXT-GENERATION SEQUENCING, BY COUNTRY, 2017–2019 (USD MILLION)
                 TABLE 25 COMPANION DIAGNOSTICS MARKET FOR NEXT-GENERATION SEQUENCING, BY COUNTRY, 2020–2025 (USD MILLION)
    8.5 IN SITU HYBRIDIZATION (ISH)
           8.5.1 ADVANCEMENTS IN ISH AND ITS DEMAND IN SMALL-TUMOR DIAGNOSTICS TO DRIVE GROWTH
                 TABLE 26 MAJOR ISH TESTS/KITS AVAILABLE IN THE MARKET
                 TABLE 27 COMPANION DIAGNOSTICS MARKET FOR IN SITU HYBRIDIZATION, BY COUNTRY, 2017–2019 (USD MILLION)
                 TABLE 28 COMPANION DIAGNOSTICS MARKET FOR IN SITU HYBRIDIZATION, BY COUNTRY, 2020–2025 (USD MILLION)
    8.6 IMMUNOHISTOCHEMISTRY (IHC)
           8.6.1 INCREASING DEMAND FOR USER-FRIENDLY AND COST-EFFECTIVE TECHNOLOGIES IN CDX TO SUPPORT GROWTH IN THIS SEGMENT
                 TABLE 29 MAJOR IHC TESTS/KITS AVAILABLE IN THE MARKET
                 TABLE 30 COMPANION DIAGNOSTICS MARKET FOR IMMUNOHISTOCHEMISTRY, BY COUNTRY, 2017–2019 (USD MILLION)
                 TABLE 31 COMPANION DIAGNOSTICS MARKET FOR IMMUNOHISTOCHEMISTRY, BY COUNTRY, 2020–2025 (USD MILLION)
    8.7 OTHER TECHNOLOGIES
        TABLE 32 COMPANION DIAGNOSTICS MARKET FOR OTHER TECHNOLOGIES, BY COUNTRY, 2017–2019 (USD MILLION)
        TABLE 33 COMPANION DIAGNOSTICS MARKET FOR OTHER TECHNOLOGIES, BY COUNTRY, 2020–2025 (USD MILLION)

9 COMPANION DIAGNOSTICS MARKET, BY INDICATION (Page No. - 111)
    9.1 INTRODUCTION
        TABLE 34 COMPANION DIAGNOSTICS MARKET, BY INDICATION, 2017–2019 (USD MILLION)
        TABLE 35 COMPANION DIAGNOSTICS MARKET, BY INDICATION, 2020–2025 (USD MILLION)
    9.2 IMPACT OF COVID-19 ON VARIOUS INDICATIONS IN THE COMPANION DIAGNOSTICS MARKET
    9.3 CANCER
        FIGURE 25 BREAST CANCER TO DOMINATE THE COMPANION DIAGNOSTICS MARKET FOR CANCER DURING THE FORECAST PERIOD
        TABLE 36 COMPANION DIAGNOSTICS MARKET FOR CANCER, BY TYPE, 2017–2019 (USD MILLION)
        TABLE 37 COMPANION DIAGNOSTICS MARKET FOR CANCER, BY TYPE, 2020–2025 (USD MILLION)
        TABLE 38 COMPANION DIAGNOSTICS MARKET FOR CANCER, BY COUNTRY, 2017–2019 (USD MILLION)
        TABLE 39 COMPANION DIAGNOSTICS MARKET FOR CANCER, BY COUNTRY, 2020–2025 (USD MILLION)
           9.3.1 BREAST CANCER
                    9.3.1.1 Breast cancer is the most common cancer among women—a key factor contributing to the large share of this market segment
                            TABLE 40 COMPANION DIAGNOSTICS MARKET FOR BREAST CANCER, BY COUNTRY, 2017–2019 (USD MILLION)
                            TABLE 41 COMPANION DIAGNOSTICS MARKET FOR BREAST CANCER, BY COUNTRY, 2020–2025 (USD MILLION)
           9.3.2 LUNG CANCER
                    9.3.2.1 Growing demand for therapeutic drugs and their high efficacy in the treatment of lung cancer to increase CDX adoption
                            FIGURE 26 GLOBAL LUNG CANCER INCIDENCE, 2012–2030
                            TABLE 42 COMPANION DIAGNOSTICS MARKET FOR LUNG CANCER, BY COUNTRY, 2017–2019 (USD MILLION)
                            TABLE 43 COMPANION DIAGNOSTICS MARKET FOR LUNG CANCER, BY COUNTRY, 2020–2025 (USD MILLION)
           9.3.3 COLORECTAL CANCER
                    9.3.3.1 Growing need for molecular profiling of primary tumors in colorectal cancer to drive growth in this market segment
                            TABLE 44 COMPANION DIAGNOSTICS MARKET FOR COLORECTAL CANCER, BY COUNTRY, 2017–2019 (USD MILLION)
                            TABLE 45 COMPANION DIAGNOSTICS MARKET FOR COLORECTAL CANCER, BY COUNTRY, 2020–2025 (USD MILLION)
           9.3.4 MELANOMA
                    9.3.4.1 Growing incidence of melanoma drives the demand for companion diagnostics
                            TABLE 46 COMPANION DIAGNOSTICS MARKET FOR MELANOMA, BY COUNTRY, 2017–2019 (USD MILLION)
                            TABLE 47 COMPANION DIAGNOSTICS MARKET FOR MELANOMA, BY COUNTRY, 2020–2025 (USD MILLION)
           9.3.5 GASTRIC CANCER
                    9.3.5.1 Increasing focus of market players on the development of tests and kits for gastric cancer indications to drive market growth
                            TABLE 48 COMPANION DIAGNOSTICS MARKET FOR GASTRIC CANCER, BY COUNTRY, 2017–2019 (USD MILLION)
                            TABLE 49 COMPANION DIAGNOSTICS MARKET FOR GASTRIC CANCER, BY COUNTRY, 2020–2025 (USD MILLION)
    9.4 INFECTIOUS DISEASES
           9.4.1 GROWING FOCUS OF COMPANION DIAGNOSTIC PLAYERS ON ORPHAN INDICATIONS TO PROPEL THE GROWTH OF THIS SEGMENT
                 TABLE 50 COMPANION DIAGNOSTICS MARKET FOR INFECTIOUS DISEASES, BY COUNTRY, 2017–2019 (USD MILLION)
                 TABLE 51 COMPANION DIAGNOSTICS MARKET FOR INFECTIOUS DISEASES, BY COUNTRY, 2020–2025 (USD MILLION)
    9.5 CARDIOVASCULAR DISEASES
           9.5.1 GROWING DEMAND FOR TARGETED THERAPIES DUE TO HIGH INCIDENCE OF CARDIOVASCULAR DISEASES TO DRIVE GROWTH
                 TABLE 52 COMPANION DIAGNOSTICS MARKET FOR CARDIOVASCULAR DISEASES, BY COUNTRY, 2017–2019 (USD MILLION)
                 TABLE 53 COMPANION DIAGNOSTICS MARKET FOR CARDIOVASCULAR DISEASES, BY COUNTRY, 2020–2025 (USD MILLION)
    9.6 NEUROLOGICAL DISEASES
           9.6.1 GROWING NUMBER OF DIAGNOSTIC TECHNOLOGIES FOR THE TREATMENT OF NEUROLOGICAL DISEASES TO BOOST THE ADOPTION OF COMPANION DIAGNOSTICS
                 TABLE 54 COMPANION DIAGNOSTICS MARKET FOR NEUROLOGICAL DISEASES, BY COUNTRY, 2017–2019 (USD MILLION)
                 TABLE 55 COMPANION DIAGNOSTICS MARKET FOR NEUROLOGICAL DISEASES, BY COUNTRY, 2020–2025 (USD MILLION)
    9.7 OTHER INDICATIONS
        TABLE 56 COMPANION DIAGNOSTICS MARKET FOR OTHER INDICATIONS, BY COUNTRY, 2017–2019 (USD MILLION)
        TABLE 57 COMPANION DIAGNOSTICS MARKET FOR OTHER INDICATIONS, BY COUNTRY, 2020–2025 (USD MILLION)

10 COMPANION DIAGNOSTICS MARKET, BY END USER (Page No. - 136)
     10.1 INTRODUCTION
          TABLE 58 COMPANION DIAGNOSTICS MARKET, BY END USER, 2017–2019 (USD MILLION)
          TABLE 59 COMPANION DIAGNOSTICS MARKET, BY END USER, 2020–2025 (USD MILLION)
     10.2 IMPACT OF COVID-19 ON THE END USERS IN THE COMPANION DIAGNOSTICS MARKET
     10.3 PHARMACEUTICAL & BIOPHARMACEUTICAL COMPANIES
             10.3.1 WIDE USAGE OF CDX IN PHARMACEUTICAL & BIOPHARMACEUTICAL COMPANIES TO DRIVE MARKET GROWTH
                    TABLE 60 COMPANION DIAGNOSTICS MARKET FOR PHARMACEUTICAL & BIOPHARMACEUTICAL COMPANIES, BY COUNTRY, 2017–2019 (USD MILLION)
                    TABLE 61 COMPANION DIAGNOSTICS MARKET FOR PHARMACEUTICAL & BIOPHARMACEUTICAL COMPANIES, BY COUNTRY, 2020–2025 (USD MILLION)
     10.4 REFERENCE LABORATORIES
             10.4.1 GROWING INCIDENCE OF AND RISING DEMAND FOR TARGETED THERAPIES TO DRIVE GROWTH
                    TABLE 62 COMPANION DIAGNOSTICS MARKET FOR REFERENCE LABORATORIES, BY COUNTRY, 2017–2019 (USD MILLION)
                    TABLE 63 COMPANION DIAGNOSTICS MARKET FOR REFERENCE LABORATORIES, BY COUNTRY, 2020–2025 (USD MILLION)
     10.5 CONTRACT RESEARCH ORGANIZATIONS
             10.5.1 CROS OFFER A COMPLETE RANGE OF COMPANION DIAGNOSTIC SERVICES TO TARGETED THERAPY-RELATED CLINICAL TRIALS
                    TABLE 64 COMPANION DIAGNOSTICS MARKET FOR CONTRACT RESEARCH ORGANIZATIONS, BY COUNTRY, 2017–2019 (USD MILLION)
                    TABLE 65 COMPANION DIAGNOSTICS MARKET FOR CONTRACT RESEARCH ORGANIZATIONS, BY COUNTRY, 2020–2025 (USD MILLION)
     10.6 OTHER END USERS
          TABLE 66 COMPANION DIAGNOSTICS MARKET FOR OTHER END USERS, BY COUNTRY, 2017–2019 (USD MILLION)
          TABLE 67 COMPANION DIAGNOSTICS MARKET FOR OTHER END USERS, BY COUNTRY, 2020–2025 (USD MILLION)

11 COMPANION DIAGNOSTICS MARKET, BY REGION (Page No. - 147)
     11.1 INTRODUCTION
          FIGURE 27 GEOGRAPHIC SNAPSHOT: CHINA IS EXPECTED TO GROW AT THE HIGHEST CAGR DURING THE FORECAST PERIOD
          TABLE 68 COMPANION DIAGNOSTICS MARKET, BY REGION, 2017–2019 (USD MILLION)
          TABLE 69 COMPANION DIAGNOSTICS MARKET, BY REGION, 2020–2025 (USD MILLION)
     11.2 IMPACT OF COVID-19 ON VARIOUS REGIONS IN THE COMPANION DIAGNOSTICS MARKET
     11.3 NORTH AMERICA
          FIGURE 28 NORTH AMERICA: COMPANION DIAGNOSTICS MARKET SNAPSHOT
          TABLE 70 NORTH AMERICA: COMPANION DIAGNOSTICS MARKET, BY COUNTRY, 2017–2019 (USD MILLION)
          TABLE 71 NORTH AMERICA: COMPANION DIAGNOSTICS MARKET, BY COUNTRY, 2020–2025 (USD MILLION)
          TABLE 72 NORTH AMERICA: COMPANION DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2017–2019 (USD MILLION)
          TABLE 73 NORTH AMERICA: COMPANION DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2020–2025 (USD MILLION)
          TABLE 74 NORTH AMERICA: COMPANION DIAGNOSTICS MARKET, BY TECHNOLOGY, 2017–2019 (USD MILLION)
          TABLE 75 NORTH AMERICA: COMPANION DIAGNOSTICS MARKET, BY TECHNOLOGY, 2020–2025 (USD MILLION)
          TABLE 76 NORTH AMERICA: COMPANION DIAGNOSTICS MARKET, BY INDICATION, 2017–2019 (USD MILLION)
          TABLE 77 NORTH AMERICA: COMPANION DIAGNOSTICS MARKET, BY INDICATION, 2020–2025 (USD MILLION)
          TABLE 78 NORTH AMERICA: COMPANION DIAGNOSTICS MARKET FOR CANCER, BY TYPE, 2017–2019 (USD MILLION)
          TABLE 79 NORTH AMERICA: COMPANION DIAGNOSTICS MARKET FOR CANCER, BY TYPE, 2020–2025 (USD MILLION)
          TABLE 80 NORTH AMERICA: COMPANION DIAGNOSTICS MARKET, BY END USER, 2017–2019 (USD MILLION)
          TABLE 81 NORTH AMERICA: COMPANION DIAGNOSTICS MARKET, BY END USER, 2020–2025 (USD MILLION)
             11.3.1 US
                        11.3.1.1 US is the largest market for companion diagnostics in North America
                                 TABLE 82 US: KEY MACROINDICATORS
                                 TABLE 83 US: COMPANION DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2017–2019 (USD MILLION)
                                 TABLE 84 US: COMPANION DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2020–2025 (USD MILLION)
                                 TABLE 85 US: COMPANION DIAGNOSTICS MARKET, BY TECHNOLOGY, 2017–2019 (USD MILLION)
                                 TABLE 86 US: COMPANION DIAGNOSTICS MARKET, BY TECHNOLOGY, 2020–2025 (USD MILLION)
                                 TABLE 87 US: COMPANION DIAGNOSTICS MARKET, BY INDICATION, 2017–2019 (USD MILLION)
                                 TABLE 88 US: COMPANION DIAGNOSTICS MARKET, BY INDICATION, 2020–2025 (USD MILLION)
                                 TABLE 89 US: COMPANION DIAGNOSTICS MARKET FOR CANCER, BY TYPE, 2017–2019 (USD MILLION)
                                 TABLE 90 US: COMPANION DIAGNOSTICS MARKET FOR CANCER, BY TYPE, 2020–2025 (USD MILLION)
                                 TABLE 91 US: COMPANION DIAGNOSTICS MARKET, BY END USER, 2017–2019 (USD MILLION)
                                 TABLE 92 US: COMPANION DIAGNOSTICS MARKET, BY END USER, 2020–2025 (USD MILLION)
             11.3.2 CANADA
                        11.3.2.1 Government initiatives to promote companion diagnostics in various indications to drive market growth in Canada
                                 TABLE 93 CANADA: KEY MACROINDICATORS
                                 TABLE 94 CANADA: COMPANION DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2017–2019 (USD MILLION)
                                 TABLE 95 CANADA: COMPANION DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2020–2025 (USD MILLION)
                                 TABLE 96 CANADA: COMPANION DIAGNOSTICS MARKET, BY TECHNOLOGY, 2017–2019 (USD MILLION)
                                 TABLE 97 CANADA: COMPANION DIAGNOSTICS MARKET, BY TECHNOLOGY, 2020–2025 (USD MILLION)
                                 TABLE 98 CANADA: COMPANION DIAGNOSTICS MARKET, BY INDICATION, 2017–2019 (USD MILLION)
                                 TABLE 99 CANADA: COMPANION DIAGNOSTICS MARKET, BY INDICATION, 2020–2025 (USD MILLION)
                                 TABLE 100 CANADA: COMPANION DIAGNOSTICS MARKET FOR CANCER, BY TYPE, 2017–2019 (USD MILLION)
                                 TABLE 101 CANADA: COMPANION DIAGNOSTICS MARKET FOR CANCER, BY TYPE, 2020–2025 (USD MILLION)
                                 TABLE 102 CANADA: COMPANION DIAGNOSTICS MARKET, BY END USER, 2017–2019 (USD MILLION)
                                 TABLE 103 CANADA: COMPANION DIAGNOSTICS MARKET, BY END USER, 2020–2025 (USD MILLION)
     11.4 EUROPE
          TABLE 104 EUROPE: COMPANION DIAGNOSTICS MARKET, BY COUNTRY, 2017–2019 (USD MILLION)
          TABLE 105 EUROPE: COMPANION DIAGNOSTICS MARKET, BY COUNTRY, 2020–2025 (USD MILLION)
          TABLE 106 EUROPE: COMPANION DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2017–2019 (USD MILLION)
          TABLE 107 EUROPE: COMPANION DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2020–2025 (USD MILLION)
          TABLE 108 EUROPE: COMPANION DIAGNOSTICS MARKET, BY TECHNOLOGY, 2017–2019 (USD MILLION)
          TABLE 109 EUROPE: COMPANION DIAGNOSTICS MARKET, BY TECHNOLOGY, 2020–2025 (USD MILLION)
          TABLE 110 EUROPE: COMPANION DIAGNOSTICS MARKET, BY INDICATION, 2017–2019 (USD MILLION)
          TABLE 111 EUROPE: COMPANION DIAGNOSTICS MARKET, BY INDICATION, 2020–2025 (USD MILLION)
          TABLE 112 EUROPE: COMPANION DIAGNOSTICS MARKET FOR CANCER, BY TYPE, 2017–2019 (USD MILLION)
          TABLE 113 EUROPE: COMPANION DIAGNOSTICS MARKET FOR CANCER, BY TYPE, 2020–2025 (USD MILLION)
          TABLE 114 EUROPE: COMPANION DIAGNOSTICS MARKET, BY END USER, 2017–2019 (USD MILLION)
          TABLE 115 EUROPE: COMPANION DIAGNOSTICS MARKET, BY END USER, 2020–2025 (USD MILLION)
             11.4.1 GERMANY
                        11.4.1.1 Germany is a major market for pharmaceutical and biotechnology products in Europe
                                 TABLE 116 GERMANY: KEY MACROINDICATORS
                                 TABLE 117 GERMANY: COMPANION DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2017–2019 (USD MILLION)
                                 TABLE 118 GERMANY: COMPANION DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2020–2025 (USD MILLION)
                                 TABLE 119 GERMANY: COMPANION DIAGNOSTICS MARKET, BY TECHNOLOGY, 2017–2019 (USD MILLION)
                                 TABLE 120 GERMANY: COMPANION DIAGNOSTICS MARKET, BY TECHNOLOGY, 2020–2025 (USD MILLION)
                                 TABLE 121 GERMANY: COMPANION DIAGNOSTICS MARKET, BY INDICATION, 2017–2019 (USD MILLION)
                                 TABLE 122 GERMANY: COMPANION DIAGNOSTICS MARKET, BY INDICATION, 2020–2025 (USD MILLION)
                                 TABLE 123 GERMANY: COMPANION DIAGNOSTICS MARKET FOR CANCER, BY TYPE, 2017–2019 (USD MILLION)
                                 TABLE 124 GERMANY: COMPANION DIAGNOSTICS MARKET FOR CANCER, BY TYPE, 2020–2025 (USD MILLION)
                                 TABLE 125 GERMANY: COMPANION DIAGNOSTICS MARKET, BY END USER, 2017–2019 (USD MILLION)
                                 TABLE 126 GERMANY: COMPANION DIAGNOSTICS MARKET, BY END USER, 2020–2025 (USD MILLION)
             11.4.2 UK
                        11.4.2.1 Growth in the country’s life science industry and increasing research are key factors driving market growth in the UK
                                 TABLE 127 UK: KEY MACROINDICATORS
                                 TABLE 128 UK: COMPANION DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2017–2019 (USD MILLION)
                                 TABLE 129 UK: COMPANION DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2020–2025 (USD MILLION)
                                 TABLE 130 UK: COMPANION DIAGNOSTICS MARKET, BY TECHNOLOGY, 2017–2019 (USD MILLION)
                                 TABLE 131 UK: COMPANION DIAGNOSTICS MARKET, BY TECHNOLOGY, 2020–2025 (USD MILLION)
                                 TABLE 132 UK: COMPANION DIAGNOSTICS MARKET, BY INDICATION, 2017–2019 (USD MILLION)
                                 TABLE 133 UK: COMPANION DIAGNOSTICS MARKET, BY INDICATION, 2020–2025 (USD MILLION)
                                 TABLE 134 UK: COMPANION DIAGNOSTICS MARKET FOR CANCER, BY TYPE, 2017–2019 (USD MILLION)
                                 TABLE 135 UK: COMPANION DIAGNOSTICS MARKET FOR CANCER, BY TYPE, 2020–2025 (USD MILLION)
                                 TABLE 136 UK: COMPANION DIAGNOSTICS MARKET, BY END USER, 2017–2019 (USD MILLION)
                                 TABLE 137 UK: COMPANION DIAGNOSTICS MARKET, BY END USER, 2020–2025 (USD MILLION)
             11.4.3 SWITZERLAND
                        11.4.3.1 Switzerland boasts a strong research-oriented pharma industry, a key factor supporting market growth
                                 TABLE 138 SWITZERLAND: KEY MACROINDICATORS
                                 TABLE 139 SWITZERLAND: COMPANION DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2017–2019 (USD MILLION)
                                 TABLE 140 SWITZERLAND: COMPANION DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2020–2025 (USD MILLION)
                                 TABLE 141 SWITZERLAND: COMPANION DIAGNOSTICS MARKET, BY TECHNOLOGY, 2017–2019 (USD MILLION)
                                 TABLE 142 SWITZERLAND: COMPANION DIAGNOSTICS MARKET, BY TECHNOLOGY, 2020–2025 (USD MILLION)
                                 TABLE 143 SWITZERLAND: COMPANION DIAGNOSTICS MARKET, BY INDICATION, 2017–2019 (USD MILLION)
                                 TABLE 144 SWITZERLAND: COMPANION DIAGNOSTICS MARKET, BY INDICATION, 2020–2025 (USD MILLION)
                                 TABLE 145 SWITZERLAND: COMPANION DIAGNOSTICS MARKET FOR CANCER, BY TYPE, 2017–2019 (USD MILLION)
                                 TABLE 146 SWITZERLAND: COMPANION DIAGNOSTICS MARKET FOR CANCER, BY TYPE, 2020–2025 (USD MILLION)
                                 TABLE 147 SWITZERLAND: COMPANION DIAGNOSTICS MARKET, BY END USER, 2017–2019 (USD MILLION)
                                 TABLE 148 SWITZERLAND: COMPANION DIAGNOSTICS MARKET, BY END USER, 2020–2025 (USD MILLION)
             11.4.4 FRANCE
                        11.4.4.1 Increasing government funding for genomics and personalized therapeutics R&D is driving market growth
                                 TABLE 149 FRANCE: KEY MACROINDICATORS
                                 TABLE 150 FRANCE: COMPANION DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2017–2019 (USD MILLION)
                                 TABLE 151 FRANCE: COMPANION DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2020–2025 (USD MILLION)
                                 TABLE 152 FRANCE: COMPANION DIAGNOSTICS MARKET, BY TECHNOLOGY, 2017–2019 (USD MILLION)
                                 TABLE 153 FRANCE: COMPANION DIAGNOSTICS MARKET, BY TECHNOLOGY, 2020–2025 (USD MILLION)
                                 TABLE 154 FRANCE: COMPANION DIAGNOSTICS MARKET, BY INDICATION, 2017–2019 (USD MILLION)
                                 TABLE 155 FRANCE: COMPANION DIAGNOSTICS MARKET, BY INDICATION, 2020–2025 (USD MILLION)
                                 TABLE 156 FRANCE: COMPANION DIAGNOSTICS MARKET FOR CANCER, BY TYPE, 2017–2019 (USD MILLION)
                                 TABLE 157 FRANCE: COMPANION DIAGNOSTICS MARKET FOR CANCER, BY TYPE, 2020–2025 (USD MILLION)
                                 TABLE 158 FRANCE: COMPANION DIAGNOSTICS MARKET, BY END USER, 2017–2019 (USD MILLION)
                                 TABLE 159 FRANCE: COMPANION DIAGNOSTICS MARKET, BY END USER, 2020–2025 (USD MILLION)
             11.4.5 ITALY
                        11.4.5.1 Growing disease prevalence has contributed to the demand for better, more powerful therapeutics in Italy
                                 TABLE 160 ITALY: KEY MACROINDICATORS
                                 TABLE 161 ITALY: COMPANION DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2017–2019 (USD MILLION)
                                 TABLE 162 ITALY: COMPANION DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2020–2025 (USD MILLION)
                                 TABLE 163 ITALY: COMPANION DIAGNOSTICS MARKET, BY TECHNOLOGY, 2017–2019 (USD MILLION)
                                 TABLE 164 ITALY: COMPANION DIAGNOSTICS MARKET, BY TECHNOLOGY, 2020–2025 (USD MILLION)
                                 TABLE 165 ITALY: COMPANION DIAGNOSTICS MARKET, BY INDICATION, 2017–2019 (USD MILLION)
                                 TABLE 166 ITALY: COMPANION DIAGNOSTICS MARKET, BY INDICATION, 2020–2025 (USD MILLION)
                                 TABLE 167 ITALY: COMPANION DIAGNOSTICS MARKET FOR CANCER, BY TYPE, 2017–2019 (USD MILLION)
                                 TABLE 168 ITALY: COMPANION DIAGNOSTICS MARKET FOR CANCER, BY TYPE, 2020–2025 (USD MILLION)
                                 TABLE 169 ITALY: COMPANION DIAGNOSTICS MARKET, BY END USER, 2017–2019 (USD MILLION)
                                 TABLE 170 ITALY: COMPANION DIAGNOSTICS MARKET, BY END USER, 2020–2025 (USD MILLION)
             11.4.6 SPAIN
                        11.4.6.1 Medical institutes in Spain are increasingly focusing on cancer biomarker research
                                 TABLE 171 SPAIN: KEY MACROINDICATORS
                                 TABLE 172 SPAIN: COMPANION DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2017–2019 (USD MILLION)
                                 TABLE 173 SPAIN: COMPANION DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2020–2025 (USD MILLION)
                                 TABLE 174 SPAIN: COMPANION DIAGNOSTICS MARKET, BY TECHNOLOGY, 2017–2019 (USD MILLION)
                                 TABLE 175 SPAIN: COMPANION DIAGNOSTICS MARKET, BY TECHNOLOGY, 2020–2025 (USD MILLION)
                                 TABLE 176 SPAIN: COMPANION DIAGNOSTICS MARKET, BY INDICATION, 2017–2019 (USD MILLION)
                                 TABLE 177 SPAIN: COMPANION DIAGNOSTICS MARKET, BY INDICATION, 2020–2025 (USD MILLION)
                                 TABLE 178 SPAIN: COMPANION DIAGNOSTICS MARKET FOR CANCER, BY TYPE, 2017–2019 (USD MILLION)
                                 TABLE 179 SPAIN: COMPANION DIAGNOSTICS MARKET FOR CANCER, BY TYPE, 2020–2025 (USD MILLION)
                                 TABLE 180 SPAIN: COMPANION DIAGNOSTICS MARKET, BY END USER, 2017–2019 (USD MILLION)
                                 TABLE 181 SPAIN: COMPANION DIAGNOSTICS MARKET, BY END USER, 2020–2025 (USD MILLION)
             11.4.7 REST OF EUROPE
                    TABLE 182 ROE: COMPANION DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2017–2019 (USD MILLION)
                    TABLE 183 ROE: COMPANION DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2020–2025 (USD MILLION)
                    TABLE 184 ROE: COMPANION DIAGNOSTICS MARKET, BY TECHNOLOGY, 2017–2019 (USD MILLION)
                    TABLE 185 ROE: COMPANION DIAGNOSTICS MARKET, BY TECHNOLOGY, 2020–2025 (USD MILLION)
                    TABLE 186 ROE: COMPANION DIAGNOSTICS MARKET, BY INDICATION, 2017–2019 (USD MILLION)
                    TABLE 187 ROE: COMPANION DIAGNOSTICS MARKET, BY INDICATION, 2020–2025 (USD MILLION)
                    TABLE 188 ROE: COMPANION DIAGNOSTICS MARKET FOR CANCER, BY TYPE, 2017–2019 (USD MILLION)
                    TABLE 189 ROE: COMPANION DIAGNOSTICS MARKET FOR CANCER, BY TYPE, 2020–2025 (USD MILLION)
                    TABLE 190 ROE: COMPANION DIAGNOSTICS MARKET, BY END USER, 2017–2019 (USD MILLION)
                    TABLE 191 ROE: COMPANION DIAGNOSTICS MARKET, BY END USER, 2020–2025 (USD MILLION)
     11.5 ASIA PACIFIC
          FIGURE 29 ASIA PACIFIC: COMPANION DIAGNOSTICS MARKET SNAPSHOT
          TABLE 192 APAC: COMPANION DIAGNOSTICS MARKET, BY COUNTRY, 2017–2019 (USD MILLION)
          TABLE 193 APAC: COMPANION DIAGNOSTICS MARKET, BY COUNTRY, 2020–2025 (USD MILLION)
          TABLE 194 APAC: COMPANION DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2017–2019 (USD MILLION)
          TABLE 195 APAC: COMPANION DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2020–2025 (USD MILLION)
          TABLE 196 APAC: COMPANION DIAGNOSTICS MARKET, BY TECHNOLOGY, 2017–2019 (USD MILLION)
          TABLE 197 APAC: COMPANION DIAGNOSTICS MARKET, BY TECHNOLOGY, 2020–2025 (USD MILLION)
          TABLE 198 APAC: COMPANION DIAGNOSTICS MARKET, BY INDICATION, 2017–2019 (USD MILLION)
          TABLE 199 APAC: COMPANION DIAGNOSTICS MARKET, BY INDICATION, 2020–2025 (USD MILLION)
          TABLE 200 APAC: COMPANION DIAGNOSTICS MARKET FOR CANCER, BY TYPE, 2017–2019 (USD MILLION)
          TABLE 201 APAC: COMPANION DIAGNOSTICS MARKET FOR CANCER, BY TYPE, 2020–2025 (USD MILLION)
          TABLE 202 APAC: COMPANION DIAGNOSTICS MARKET, BY END USER, 2017–2019 (USD MILLION)
          TABLE 203 APAC: COMPANION DIAGNOSTICS MARKET, BY END USER, 2020–2025 (USD MILLION)
             11.5.1 JAPAN
                        11.5.1.1 Japan holds the second largest share of the market in APAC
                                 TABLE 204 JAPAN: KEY MACROINDICATORS
                                 TABLE 205 JAPAN: COMPANION DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2017–2019 (USD MILLION)
                                 TABLE 206 JAPAN: COMPANION DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2020–2025 (USD MILLION)
                                 TABLE 207 JAPAN: COMPANION DIAGNOSTICS MARKET, BY TECHNOLOGY, 2017–2019 (USD MILLION)
                                 TABLE 208 JAPAN: COMPANION DIAGNOSTICS MARKET, BY TECHNOLOGY, 2020–2025 (USD MILLION)
                                 TABLE 209 JAPAN: COMPANION DIAGNOSTICS MARKET, BY INDICATION, 2017–2019 (USD MILLION)
                                 TABLE 210 JAPAN: COMPANION DIAGNOSTICS MARKET, BY INDICATION, 2020–2025 (USD MILLION)
                                 TABLE 211 JAPAN: COMPANION DIAGNOSTICS MARKET FOR CANCER, BY TYPE, 2017–2019 (USD MILLION)
                                 TABLE 212 JAPAN: COMPANION DIAGNOSTICS MARKET FOR CANCER, BY TYPE, 2020–2025 (USD MILLION)
                                 TABLE 213 JAPAN: COMPANION DIAGNOSTICS MARKET, BY END USER, 2017–2019 (USD MILLION)
                                 TABLE 214 JAPAN: COMPANION DIAGNOSTICS MARKET, BY END USER, 2020–2025 (USD MILLION)
             11.5.2 CHINA
                        11.5.2.1 China is one of the most prominent research markets, worldwide
                                 TABLE 215 CHINA: KEY MACROINDICATORS
                                 TABLE 216 CHINA: COMPANION DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2017–2019 (USD MILLION)
                                 TABLE 217 CHINA: COMPANION DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2020–2025 (USD MILLION)
                                 TABLE 218 CHINA: COMPANION DIAGNOSTICS MARKET, BY TECHNOLOGY, 2017–2019 (USD MILLION)
                                 TABLE 219 CHINA: COMPANION DIAGNOSTICS MARKET, BY TECHNOLOGY, 2020–2025 (USD MILLION)
                                 TABLE 220 CHINA: COMPANION DIAGNOSTICS MARKET, BY INDICATION, 2017–2019 (USD MILLION)
                                 TABLE 221 CHINA: COMPANION DIAGNOSTICS MARKET, BY INDICATION, 2020–2025 (USD MILLION)
                                 TABLE 222 CHINA: COMPANION DIAGNOSTICS MARKET FOR CANCER, BY TYPE, 2017–2019 (USD MILLION)
                                 TABLE 223 CHINA: COMPANION DIAGNOSTICS MARKET FOR CANCER, BY TYPE, 2020–2025 (USD MILLION)
                                 TABLE 224 CHINA: COMPANION DIAGNOSTICS MARKET, BY END USER, 2017–2019 (USD MILLION)
                                 TABLE 225 CHINA: COMPANION DIAGNOSTICS MARKET, BY END USER, 2020–2025 (USD MILLION)
             11.5.3 INDIA
                        11.5.3.1 Government initiatives to tackle the growing burden of cancer are expected to increase the adoption of CDX in the country
                                 TABLE 226 INDIA: KEY MACROINDICATORS
                                 TABLE 227 INDIA: COMPANION DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2017–2019 (USD MILLION)
                                 TABLE 228 INDIA: COMPANION DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2020–2025 (USD MILLION)
                                 TABLE 229 INDIA: COMPANION DIAGNOSTICS MARKET, BY TECHNOLOGY, 2017–2019 (USD MILLION)
                                 TABLE 230 INDIA: COMPANION DIAGNOSTICS MARKET, BY TECHNOLOGY, 2020–2025 (USD MILLION)
                                 TABLE 231 INDIA: COMPANION DIAGNOSTICS MARKET, BY INDICATION, 2017–2019 (USD MILLION)
                                 TABLE 232 INDIA: COMPANION DIAGNOSTICS MARKET, BY INDICATION, 2020–2025 (USD MILLION)
                                 TABLE 233 INDIA: COMPANION DIAGNOSTICS MARKET FOR CANCER, BY TYPE, 2017–2019 (USD MILLION)
                                 TABLE 234 INDIA: COMPANION DIAGNOSTICS MARKET FOR CANCER, BY TYPE, 2020–2025 (USD MILLION)
                                 TABLE 235 INDIA: COMPANION DIAGNOSTICS MARKET, BY END USER, 2017–2019 (USD MILLION)
                                 TABLE 236 INDIA: COMPANION DIAGNOSTICS MARKET, BY END USER, 2020–2025 (USD MILLION)
             11.5.4 AUSTRALIA
                        11.5.4.1 Growing geriatric population in Australia has resulted in initiatives to enhance healthcare access and infrastructure
                                 TABLE 237 AUSTRALIA: KEY MACROINDICATORS
                                 TABLE 238 AUSTRALIA: COMPANION DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2017–2019 (USD MILLION)
                                 TABLE 239 AUSTRALIA: COMPANION DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2020–2025 (USD MILLION)
                                 TABLE 240 AUSTRALIA: COMPANION DIAGNOSTICS MARKET, BY TECHNOLOGY, 2017–2019 (USD MILLION)
                                 TABLE 241 AUSTRALIA: COMPANION DIAGNOSTICS MARKET, BY TECHNOLOGY, 2020–2025 (USD MILLION)
                                 TABLE 242 AUSTRALIA: COMPANION DIAGNOSTICS MARKET, BY INDICATION, 2017–2019 (USD MILLION)
                                 TABLE 243 AUSTRALIA: COMPANION DIAGNOSTICS MARKET, BY INDICATION, 2020–2025 (USD MILLION)
                                 TABLE 244 AUSTRALIA: COMPANION DIAGNOSTICS MARKET FOR CANCER, BY TYPE, 2017–2019 (USD MILLION)
                                 TABLE 245 AUSTRALIA: COMPANION DIAGNOSTICS MARKET FOR CANCER, BY TYPE, 2020–2025 (USD MILLION)
                                 TABLE 246 AUSTRALIA: COMPANION DIAGNOSTICS MARKET, BY END USER, 2017–2019 (USD MILLION)
                                 TABLE 247 AUSTRALIA: COMPANION DIAGNOSTICS MARKET, BY END USER, 2020–2025 (USD MILLION)
             11.5.5 REST OF ASIA PACIFIC
                    TABLE 248 ROAPAC: COMPANION DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2017–2019 (USD MILLION)
                    TABLE 249 ROAPAC: COMPANION DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2020–2025 (USD MILLION)
                    TABLE 250 ROAPAC: COMPANION DIAGNOSTICS MARKET, BY TECHNOLOGY, 2017–2019 (USD MILLION)
                    TABLE 251 ROAPAC: COMPANION DIAGNOSTICS MARKET, BY TECHNOLOGY, 2020–2025 (USD MILLION)
                    TABLE 252 ROAPAC: COMPANION DIAGNOSTICS MARKET, BY INDICATION, 2017–2019 (USD MILLION)
                    TABLE 253 ROAPAC: COMPANION DIAGNOSTICS MARKET, BY INDICATION, 2020–2025 (USD MILLION)
                    TABLE 254 ROAPAC: COMPANION DIAGNOSTICS MARKET FOR CANCER, BY TYPE, 2017–2019 (USD MILLION)
                    TABLE 255 ROAPAC: COMPANION DIAGNOSTICS MARKET FOR CANCER, BY TYPE, 2020–2025 (USD MILLION)
                    TABLE 256 ROAPAC: COMPANION DIAGNOSTICS MARKET, BY END USER, 2017–2019 (USD MILLION)
                    TABLE 257 ROAPAC: COMPANION DIAGNOSTICS MARKET, BY END USER, 2020–2025 (USD MILLION)
     11.6 LATIN AMERICA
          TABLE 258 LATIN AMERICA: COMPANION DIAGNOSTICS MARKET, BY COUNTRY, 2017–2019 (USD MILLION)
          TABLE 259 LATIN AMERICA: COMPANION DIAGNOSTICS MARKET, BY COUNTRY, 2020–2025 (USD MILLION)
          TABLE 260 LATIN AMERICA: COMPANION DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2017–2019 (USD MILLION)
          TABLE 261 LATIN AMERICA: COMPANION DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2020–2025 (USD MILLION)
          TABLE 262 LATIN AMERICA: COMPANION DIAGNOSTICS MARKET, BY TECHNOLOGY, 2017–2019 (USD MILLION)
          TABLE 263 LATIN AMERICA: COMPANION DIAGNOSTICS MARKET, BY TECHNOLOGY, 2020–2025 (USD MILLION)
          TABLE 264 LATIN AMERICA: COMPANION DIAGNOSTICS MARKET, BY INDICATION, 2017–2019 (USD MILLION)
          TABLE 265 LATIN AMERICA: COMPANION DIAGNOSTICS MARKET, BY INDICATION, 2020–2025 (USD MILLION)
          TABLE 266 LATIN AMERICA: COMPANION DIAGNOSTICS MARKET FOR CANCER, BY TYPE, 2017–2019 (USD MILLION)
          TABLE 267 LATIN AMERICA: COMPANION DIAGNOSTICS MARKET FOR CANCER, BY TYPE, 2020–2025 (USD MILLION)
          TABLE 268 LATIN AMERICA: COMPANION DIAGNOSTICS MARKET, BY END USER, 2017–2019 (USD MILLION)
          TABLE 269 LATIN AMERICA: COMPANION DIAGNOSTICS MARKET, BY END USER, 2020–2025 (USD MILLION)
             11.6.1 BRAZIL
                        11.6.1.1 Brazil dominates the Latin American companion diagnostics market
                                 TABLE 270 BRAZIL: KEY MACROINDICATORS
                                 TABLE 271 BRAZIL: COMPANION DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2017–2019 (USD MILLION)
                                 TABLE 272 BRAZIL: COMPANION DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2020–2025 (USD MILLION)
                                 TABLE 273 BRAZIL: COMPANION DIAGNOSTICS MARKET, BY TECHNOLOGY, 2017–2019 (USD MILLION)
                                 TABLE 274 BRAZIL: COMPANION DIAGNOSTICS MARKET, BY TECHNOLOGY, 2020–2025 (USD MILLION)
                                 TABLE 275 BRAZIL: COMPANION DIAGNOSTICS MARKET, BY INDICATION, 2017–2019 (USD MILLION)
                                 TABLE 276 BRAZIL: COMPANION DIAGNOSTICS MARKET, BY INDICATION, 2020–2025 (USD MILLION)
                                 TABLE 277 BRAZIL: COMPANION DIAGNOSTICS MARKET FOR CANCER, BY TYPE, 2017–2019 (USD MILLION)
                                 TABLE 278 BRAZIL: COMPANION DIAGNOSTICS MARKET FOR CANCER, BY TYPE, 2020–2025 (USD MILLION)
                                 TABLE 279 BRAZIL: COMPANION DIAGNOSTICS MARKET, BY END USER, 2017–2019 (USD MILLION)
                                 TABLE 280 BRAZIL: COMPANION DIAGNOSTICS MARKET, BY END USER, 2020–2025 (USD MILLION)
             11.6.2 MEXICO
                        11.6.2.1 Mexico is emerging as a prominent medical tourism hub
                                 TABLE 281 MEXICO: KEY MACROINDICATORS
                                 TABLE 282 MEXICO: COMPANION DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2017–2019 (USD MILLION)
                                 TABLE 283 MEXICO: COMPANION DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2020–2025 (USD MILLION)
                                 TABLE 284 MEXICO: COMPANION DIAGNOSTICS MARKET, BY TECHNOLOGY, 2017–2019 (USD MILLION)
                                 TABLE 285 MEXICO: COMPANION DIAGNOSTICS MARKET, BY TECHNOLOGY, 2020–2025 (USD MILLION)
                                 TABLE 286 MEXICO: COMPANION DIAGNOSTICS MARKET, BY INDICATION, 2017–2019 (USD MILLION)
                                 TABLE 287 MEXICO: COMPANION DIAGNOSTICS MARKET, BY INDICATION, 2020–2025 (USD MILLION)
                                 TABLE 288 MEXICO: COMPANION DIAGNOSTICS MARKET FOR CANCER, BY TYPE, 2017–2019 (USD MILLION)
                                 TABLE 289 MEXICO: COMPANION DIAGNOSTICS MARKET FOR CANCER, BY TYPE, 2020–2025 (USD MILLION)
                                 TABLE 290 MEXICO: COMPANION DIAGNOSTICS MARKET, BY END USER, 2017–2019 (USD MILLION)
                                 TABLE 291 MEXICO: COMPANION DIAGNOSTICS MARKET, BY END USER, 2020–2025 (USD MILLION)
             11.6.3 REST OF LATIN AMERICA
                    TABLE 292 ROLA: COMPANION DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2017–2019 (USD MILLION)
                    TABLE 293 ROLA: COMPANION DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2020–2025 (USD MILLION)
                    TABLE 294 ROLA: COMPANION DIAGNOSTICS MARKET, BY TECHNOLOGY, 2017–2019 (USD MILLION)
                    TABLE 295 ROLA: COMPANION DIAGNOSTICS MARKET, BY TECHNOLOGY, 2020–2025 (USD MILLION)
                    TABLE 296 ROLA: COMPANION DIAGNOSTICS MARKET, BY INDICATION, 2017–2019 (USD MILLION)
                    TABLE 297 ROLA: COMPANION DIAGNOSTICS MARKET, BY INDICATION, 2020–2025 (USD MILLION)
                    TABLE 298 ROLA: COMPANION DIAGNOSTICS MARKET FOR CANCER, BY TYPE, 2017–2019 (USD MILLION)
                    TABLE 299 ROLA: COMPANION DIAGNOSTICS MARKET FOR CANCER, BY TYPE, 2020–2025 (USD MILLION)
                    TABLE 300 ROLA: COMPANION DIAGNOSTICS MARKET, BY END USER, 2017–2019 (USD MILLION)
                    TABLE 301 ROLA: COMPANION DIAGNOSTICS MARKET, BY END USER, 2020–2025 (USD MILLION)
     11.7 MIDDLE EAST & AFRICA
             11.7.1 RISING CANCER INCIDENCE RATE HAS ATTRACTED STAKEHOLDER ATTENTION TO REGIONAL MARKETS IN MEA
                    TABLE 302 MEA: COMPANION DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2017–2019 (USD MILLION)
                    TABLE 303 MEA: COMPANION DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2020–2025 (USD MILLION)
                    TABLE 304 MEA: COMPANION DIAGNOSTICS MARKET, BY TECHNOLOGY, 2017–2019 (USD MILLION)
                    TABLE 305 MEA: COMPANION DIAGNOSTICS MARKET, BY TECHNOLOGY, 2020–2025 (USD MILLION)
                    TABLE 306 MEA: COMPANION DIAGNOSTICS MARKET, BY INDICATION, 2017–2019 (USD MILLION)
                    TABLE 307 MEA: COMPANION DIAGNOSTICS MARKET, BY INDICATION, 2020–2025 (USD MILLION)
                    TABLE 308 MEA: COMPANION DIAGNOSTICS MARKET FOR CANCER, BY TYPE, 2017–2019 (USD MILLION)
                    TABLE 309 MEA: COMPANION DIAGNOSTICS MARKET FOR CANCER, BY TYPE, 2020–2025 (USD MILLION)
                    TABLE 310 MEA: COMPANION DIAGNOSTICS MARKET, BY END USER, 2017–2019 (USD MILLION)
                    TABLE 311 MEA: COMPANION DIAGNOSTICS MARKET, BY END USER, 2020–2025 (USD MILLION)

12 COMPETITIVE LANDSCAPE (Page No. - 262)
     12.1 OVERVIEW
          FIGURE 30 KEY DEVELOPMENTS IN THE COMPANION DIAGNOSTICS MARKET BETWEEN JANUARY 2017 AND MAY 2020
          TABLE 312 GROWTH STRATEGY MATRIX (2017–2020)
     12.2 MARKET SHARE ANALYSIS
          FIGURE 31 COMPANION DIAGNOSTICS MARKET SHARE ANALYSIS, BY KEY PLAYER, 2019
     12.3 COMPETITIVE LEADERSHIP MAPPING, 2019
     12.4 VENDOR INCLUSION CRITERIA
     12.5 VENDOR DIVE
             12.5.1 STARS
             12.5.2 EMERGING LEADERS
             12.5.3 EMERGING COMPANIES
             12.5.4 PERVASIVE PLAYERS
                    FIGURE 32 COMPANION DIAGNOSTICS MARKET COMPETITIVE LEADERSHIP MAPPING, 2019
     12.6 COMPETITIVE SITUATIONS AND TRENDS
          FIGURE 33 PRODUCT LAUNCHES & APPROVALS WAS THE KEY GROWTH STRATEGY ADOPTED BY MAJOR PLAYERS BETWEEN 2017 & 2020
          TABLE 313 PRODUCT LAUNCHES & APPROVALS, 2017–2020
             12.6.1 PARTNERSHIPS, COLLABORATIONS, AND AGREEMENTS
                    TABLE 314 PARTNERSHIPS, COLLABORATIONS, AND AGREEMENTS, 2017–2020
             12.6.2 ACQUISITIONS
                    TABLE 315 ACQUISITIONS, 2017–2020
                    TABLE 316 EXPANSIONS, 2017-2020

13 COMPANY PROFILES (Page No. - 272)
     13.1 F. HOFFMANN-LA ROCHE AG
          FIGURE 34 F. HOFFMANN-LA ROCHE AG: COMPANY SNAPSHOT
     13.2 AGILENT TECHNOLOGIES, INC.
          FIGURE 35 AGILENT TECHNOLOGIES, INC.: COMPANY SNAPSHOT
     13.3 QIAGEN N.V.
          FIGURE 36 QIAGEN N.V.: COMPANY SNAPSHOT
     13.4 THERMO FISHER SCIENTIFIC, INC.
          FIGURE 37 THERMO FISHER SCIENTIFIC: COMPANY SNAPSHOT
     13.5 ABBOTT LABORATORIES, INC.
          FIGURE 38 ABBOTT LABORATORIES, INC.: COMPANY SNAPSHOT
     13.6 ALMAC GROUP
     13.7 DANAHER CORPORATION
          FIGURE 39 DANAHER CORPORATION: COMPANY SNAPSHOT
     13.8 ILLUMINA INC.
          FIGURE 40 ILLUMINA INC.: COMPANY SNAPSHOT
     13.9 BIOMΙRIEUX SA
          FIGURE 41 BIOMΙRIEUX SA: COMPANY SNAPSHOT
     13.10 MYRIAD GENETICS, INC.
           FIGURE 42 MYRIAD GENETICS, INC.: COMPANY SNAPSHOT
     13.11 SYSMEX CORPORATION
           FIGURE 43 SYSMEX CORPORATION: COMPANY SNAPSHOT
     13.12 ABNOVA CORPORATION
     13.13 GUARDANT HEALTH, INC.
           FIGURE 44 GUARDANT HEALTH, INC.: COMPANY SNAPSHOT
     13.14 ICON PLC
           FIGURE 45 ICON PLC: COMPANY SNAPSHOT
     13.15 BIOGENEX LABORATORIES, INC.
     13.16 OTHER COMPANIES
             13.16.1 INVIVOSCRIBE TECHNOLOGIES
             13.16.2 ARCHERDX, INC.
             13.16.3 NG BIOTECH
             13.16.4 Q² SOLUTIONS
             13.16.5 AMOY DIAGNOSTICS CO., LTD.

14 ADJACENT AND RELATED MARKETS CHAPTER (Page No. - 316)
     14.1 INTRODUCTION
     14.2 MOLECULAR DIAGNOSTICS MARKET
             14.2.1 MARKET DEFINITION
             14.2.2 LIMITATIONS
             14.2.3 MARKET OVERVIEW
     14.3 MOLECULAR DIAGNOSTICS MARKET, BY REGION
          TABLE 317 MOLECULAR DIAGNOSTICS MARKET, BY REGION, 2016–2023 (USD MILLION)
     14.4 MOLECULAR DIAGNOSTICS MARKET, BY TECHNOLOGY
          TABLE 318 MOLECULAR DIAGNOSTICS MARKET, BY TECHNOLOGY, 2016–2023 (USD MILLION)
             14.4.1 POLYMERASE CHAIN REACTION (PCR)
                    TABLE 319 MOLECULAR DIAGNOSTICS MARKET FOR PCR, BY REGION, 2016–2023 (USD MILLION)
             14.4.2 ISOTHERMAL NUCLEIC ACID AMPLIFICATION TECHNOLOGY (INAAT)
                    TABLE 320 MOLECULAR DIAGNOSTICS MARKET FOR INAAT, BY REGION, 2016–2023 (USD MILLION)
             14.4.3 DNA SEQUENCING & NEXT-GENERATION SEQUENCING (NGS)
                    TABLE 321 MOLECULAR DIAGNOSTICS MARKET FOR DNA SEQUENCING AND NGS, BY REGION, 2016–2023 (USD MILLION)
             14.4.4 IN SITU HYBRIDIZATION
                    TABLE 322 MOLECULAR DIAGNOSTICS MARKET FOR IN SITU HYBRIDIZATION, BY REGION, 2016–2023 (USD MILLION)
             14.4.5 DNA MICROARRAY
                    TABLE 323 MOLECULAR DIAGNOSTICS MARKET FOR DNA MICROARRAY, BY REGION, 2016-2023 (USD MILLION)
             14.4.6 OTHER TECHNOLOGIES
                    TABLE 324 MOLECULAR DIAGNOSTICS MARKET FOR OTHER TECHNOLOGIES, BY REGION, 2016–2023 (USD MILLION)
     14.5 MOLECULAR DIAGNOSTICS MARKET, BY END USER
          TABLE 325 MOLECULAR DIAGNOSTICS MARKET, BY END USER, 2016–2023 (USD MILLION)
             14.5.1 HOSPITAL & ACADEMIC LABORATORIES
                    TABLE 326 MOLECULAR DIAGNOSTICS MARKET FOR HOSPITAL & ACADEMIC LABORATORIES, BY REGION, 2016–2023 (USD MILLION)
             14.5.2 REFERENCE LABORATORIES
                    TABLE 327 MOLECULAR DIAGNOSTICS MARKET FOR REFERENCE LABORATORIES, BY REGION, 2016–2023 (USD MILLION)
             14.5.3 OTHER END USERS
                    TABLE 328 MOLECULAR DIAGNOSTICS MARKET FOR OTHER END USERS, BY REGION, 2016–2023 (USD MILLION)

15 APPENDIX (Page No. - 324)
     15.1 INSIGHTS FROM INDUSTRY EXPERTS
     15.2 DISCUSSION GUIDE
     15.3 KNOWLEDGE STORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL
     15.4 AVAILABLE CUSTOMIZATIONS
     15.5 RELATED REPORTS
     15.6 AUTHOR DETAILS

This study involved four major activities for estimating the current size of the global companion diagnostics market. Exhaustive secondary research was conducted to collect information on the market as well as its peer and parent markets. The next step focused on validating these findings, assumptions, and sizing with industry experts across the value chain through primary research. Both the top-down and bottom-up approaches were employed to estimate the complete market size. After that, market breakdown and data triangulation were used to estimate the sizes of segments and sub-segments.

Secondary Research

In the secondary research process, various secondary sources such as D&B Hoovers, Bloomberg Business, and Factiva have been referred to identify and collect information for this study. These secondary sources include annual reports, press releases and investor presentations of companies, white papers, certified publications, articles by recognized authors, gold-standard and silver-standard websites, regulatory bodies, and databases.

Primary Research

In the primary research process, various sources from both the supply and demand sides were interviewed to obtain qualitative and quantitative information for this report. Primary sources from the supply side include industry experts such as CEOs, vice presidents, marketing and sales directors, technology and innovation directors, and related key executives from various key companies operating in the companion diagnostics market. Primary sources from the demand side include experts from hospitals and diagnostic labs and research and academic laboratories. Primary research was conducted to validate the market segmentation, identify key players in the market, and gather insights on the key industry trends and key market dynamics, such as market drivers, restraints, challenges, and opportunities.

Companion Diagnostics Market Size, and Share

To know about the assumptions considered for the study, download the pdf brochure

Market Size Estimation

The total size of the companion diagnostics market was arrived at after data triangulation from two different approaches, as mentioned below.

Approach to calculate the revenue of different players in the companion diagnostics market

The size of the global companion diagnostics market was obtained from annual reports, SEC filings, online publications, and extensive primary interviews. A percentage split was applied to arrive at the size of market segments. Further splits were applied to arrive at the size for each sub-segment. These percentage splits were validated by primary participants. The country-level market sizes obtained from the annual reports, SEC filings, online publications, and extensive primary interviews were added up to reach the total market size for regions. By adding up the market sizes for all the regions, the global companion diagnostics market was derived.

Approach to derive the market size and estimate market growth

The market size and market growth were estimated through primary interviews on a regional and global level. All responses were collated, and a weighted average was taken to derive a probabilistic estimate of the market size and growth rate.

Data Triangulation

After arriving at the overall market size—using the market size estimation processes explained above—the market was split into several segments and sub-segments. To complete the overall market engineering process and arrive at the exact statistics of each market segment and sub-segment, the data triangulation and market breakdown procedures were employed, wherever applicable. The data was triangulated by studying various factors and trends from both the demand and supply sides.

Objectives of the Study

  • To define, describe, and forecast the companion diagnostics market based on products & services, technology, indication, end user, and region
  • To provide detailed information regarding the major factors influencing market growth (such as drivers, restraints, opportunities, and challenges)
  • To strategically analyze micromarkets with respect to individual growth trends, prospects, and contributions to the total market
  • To analyze opportunities in the market for stakeholders and provide details of the competitive landscape for market leaders
  • To forecast the size of the market segments with respect to five major regions, namely, North America, Europe, the Asia Pacific, Latin America, and the Middle East and Africa
  • To profile key market players and comprehensively analyze their product portfolios, market shares, and core competencies
  • To track and analyze competitive developments, such as product launches, expansions, acquisitions, agreements, and collaborations in the companion diagnostics market

Available Customizations

With the given market data, MarketsandMarkets offers customizations as per the company’s specific needs. The following customization options are available for the report:

Geographic Analysis

  • Further breakdown of the Rest of Europe companion diagnostics market
  • Further breakdown of the Rest of Asia Pacific companion diagnostics market

Company Information

  • Detailed analysis and profiling of additional market players
COVID-19

Get in-depth analysis of the COVID-19 impact on the Companion Diagnostics Market

Benchmarking the rapid strategy shifts of the Top 100 companies in the Companion Diagnostics Market

Request For Special Pricing
Report Code
MD 5463
Published ON
Jun, 2020
Choose License Type
BUY NOW
  • SHARE
X
Request Customization
Speak to Analyst
Speak to Analyst
OR FACE-TO-FACE MEETING
PERSONALIZE THIS RESEARCH
  • Triangulate with your Own Data
  • Get Data as per your Format and Definition
  • Gain a Deeper Dive on a Specific Application, Geography, Customer or Competitor
  • Any level of Personalization
REQUEST A FREE CUSTOMIZATION
LET US HELP YOU!
  • What are the Known and Unknown Adjacencies Impacting the Companion Diagnostics Market
  • What will your New Revenue Sources be?
  • Who will be your Top Customer; what will make them switch?
  • Defend your Market Share or Win Competitors
  • Get a Scorecard for Target Partners
CUSTOMIZED WORKSHOP REQUEST
ADJACENT MARKETS
REQUEST BUNDLE REPORTS
+1-888-600-6441
  • Call Us
  • +1-888-600-6441 (Corporate office hours)
  • +1-888-600-6441 (US/Can toll free)
  • +44-800-368-9399 (UK office hours)
CONNECT WITH US
ABOUT TRUST ONLINE
©2020 MarketsandMarkets Research Private Ltd. All rights reserved
...

Digital Virtual Assistant - MarketsandMarkets

Home